目的 评价神经节苷脂对脑瘫患儿的疗效及安全性,为其临床应用提供参考。方法 检索Pubmed、Embase、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库及万方数字化全文期刊数据库,检索时间为建库至2015年10月。纳入有关神经节苷脂治疗脑瘫患儿的随机对照试验,对显效、有效率进行有序分类变量的Meta分析;对总有效率进行二分类变量的Meta分析;对患儿发育商评分(developmental quotient,DQ)进行连续变量的Meta分析。结果 共纳入10个随机对照试验,共计806例患儿,对显效、有效率分析,其相对危险度(odds ratio,OR)为2.63,95%CI:1.95~3.53;对总有效率进行分析,其OR值为4.74,95%CI:2.99~7.52;神经节苷脂使DQ评分提高,SMD=1.30,95%CI:0.33~2.27。结论 神经节苷脂对脑瘫患儿治疗效果良好,可改善患儿的症状。
Abstract
Objective To evaluate the efficacy and safety of gangliosides in the treatment of children with cerebral palsy,to provide some evidence for its clinical application. Methods The papers related to gangliosides in the treatment of children with cerebral palsy were searched in PubMed,EMBASE,Cochrane library,CBM,CNKI,CSPD (form establishments to October 2015).Randomized controlled trials on the treatment of cerebral palsy with gangliosides were included and assessed for quality.A Meta-analysis was conducted to evaluate the effectual rate and effective rate of the trials as ordinal categorical variable,to evaluate the total effective rate as binary variable,to evaluate the DQ(developmental quotient) value as continuous variable. Results A total of 10 randomized controlled trial 806 cases of children were included in the study,the OR(odds ratio) values of effectual and effective rate was 2.63 (1.95~3.53);the OR value of total effective rate was 4.74 (2.99~7.52);the DQ scores were increased,SMD=1.30,95%CI=0.33~2.27. Conclusion The efficacy of gangliosides in the treatment of children with cerebral palsy is well,and the DQ value of the children are improved.
关键词
神经节苷脂 /
脑瘫 /
Meta分析
Key words
gangliosides /
cerebral palsy /
meta-analysis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 李晓捷.《脑瘫指南及定义、分型、诊断标准修订》[A].中国康复医学会儿童康复专业委员会、中国残疾人康复协会小儿脑瘫康复专业委员会.第六届全国儿童康复、第十三届全国小儿脑瘫康复学术会议暨国际学术交流会议论文汇编[C].中国康复医学会儿童康复专业委员会、中国残疾人康复协会小儿脑瘫康复专业委员会,2014:13.
[2] 敖美卿,李小瑜,陈少君.脑瘫患儿父母的心理状况调查及对策[J].现代临床护理,2008,7(2):10-11.
[3] Van N B K,Christensen D,Doernberg N,et al.Trends in the prevalence of autism spectrum disorder,cerebral palsy,hearing loss,intellectual disability,and vision impairment,metropolitan atlanta,1991-2010[J].PloS One,2015,10(4):e0124120.
[4] 张喆庆,苏宜香.神经节苷脂与脑发育[J].卫生研究,2015,44(1):147-150.
[5] Furukawa K,Ohmi Y,Ohkawa Y,etal.Regulatory mechanisms of nervous systems with glycosphingolipids[J].Neurochem Res,2011,36 (9),1578-1586.
[6] Yu RK,Tsai YT,Ariga T.Functional roles of gangliosides in neurodevelopment:an overview of recent advances[J].Neurochem Res,2012,37(6):1230-1244.
[7] 罗林荫,杨凡,李晋蓉,等.神经节苷脂对脑瘫患儿疗效的meta分析[J].中华妇幼临床医学杂志,2009,5(3):12-14.
[8] 万鸽.神经节苷脂在小儿脑瘫中的治疗效果分析[J].中国实用医药,2015,06(1):183-184.
[9] 戚拥军,赵晓忠,高娜.综合康复与神经节苷脂联合治疗小儿脑性瘫痪的临床分析[J].齐齐哈尔医学院学报,2015,32(07):1003-1004.
[10] 宋静,许秀金,邹耀明,等.综合康复联合神经节苷脂治疗小儿脑性瘫痪的临床研究[J].齐齐哈尔医学院学报,2015,32(06):844-845.
[11] 张亚芹.神经节苷脂治疗小儿脑瘫临床疗效观察[J].现代诊断与治疗,2015,26(09):2013-2014.
[12] 温剑武.综合康复联合神经节苷脂治疗小儿脑性瘫痪的疗效观察[J].中国当代医药,2013,20(8):68-69.
[13] 陈会新,任秀云.神经节苷脂治疗小儿脑瘫40例疗效观察[J].中国实用医药,2011,6(1):142-143.
[14] 王红怡.神经节苷脂治疗小儿脑性瘫痪60例疗效观察[J].山东医药,2009,49(33):95-96.
[15] 卢国君,王永.神经节苷脂治疗婴幼儿脑性瘫痪42例[J].实用医学杂志,2009,25(13):2145-2146.
[16] 傅大林,张跃,汤健,等.单唾液酸四己糖神经节苷脂治疗小儿脑性瘫痪44例疗效观察[J].山东医药,2009,49(45):107.
[17] 李唯,王春,王燕,等.神经节苷脂治疗小儿脑性瘫痪的疗效观察(附110例报告)[J].贵州医药,2008,32(8):700-701.
[18] 宁娜,陈乃宏.神经节苷脂的生物学活性[J].生理科学进展,2009,40(1):24-30.
PDF(531 KB)
